Mark Jeffrey DeLong - 10 Feb 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Senior Vice President
Signature: /s/ David Watson, attorney-in-fact for Mark Delong
Issuer symbol: APLS
Transactions as of: 10 Feb 2022
Net transactions value: -$12,770
Form type: 4
Filing time: 14 Feb 2022, 15:13:54 UTC
Previous filing: 01 Feb 2022
Next filing: 22 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Tax liability	$12,770	-271	-1.1%	$47.12	23,580	10 Feb 2022	Direct	F1
transaction	APLS	Common Stock	Award	$0	+4,901	+21%	$0.000000	28,481	10 Feb 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$0	+6,952		$0.000000	6,952	10 Feb 2022	Common Stock	6,952	$47.12	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents shares used to cover tax withholding on a Restricted Stock Unit release.
F2	This represents a restricted stock unit grant made on February 10, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
F3	This represents a non-qualified stock option grant made on February 10, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.